New Oral Contraceptive, Loestrin(R) 24 Fe, Approved By FDA
Main Category: Women's Health / GynecologyArticle Date: 21 Feb 2006 - 6:00 PDT
email to a friend 
printer friendly 
opinions
| Patient / Public: |  |
2.34 (53 votes) |
| Healthcare Prof: |  |
2.69 (13 votes) |
Warner Chilcott announced today that the U.S. Food and Drug Administration (FDA) has approved its 24-day oral contraceptive, Loestrin(R) 24 Fe (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), for the prevention of pregnancy. Loestrin 24 Fe ("Loestrin 24") is the first birth-control pill approved in the United States that provides 24 days of active hormonal therapy and four days of iron containing placebo pills.
"This FDA approval is a significant step forward for Warner Chilcott as we continue to sharpen our therapeutic focus on women's health and expand our product portfolio in this area," said Roger Boissonneault, Chief Executive Officer of Warner Chilcott.
Warner Chilcott is a specialty pharmaceutical company focused on two areas: women's healthcare and dermatology.
Warner Chilcott
http://www.warnerchilcott.com
Visit our women's health / gynecology section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/38092.php>
APA
http://www.medicalnewstoday.com/releases/38092.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
